U.S. market Closed. Opens in 16 hours 27 minutes

RXST | RxSight, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 34.32 - 35.32
52 Week Range 33.03 - 66.54
Beta 1.11
Implied Volatility 53.98%
IV Rank 16.00%
Day's Volume 453,672
Average Volume 610,075
Shares Outstanding 40,304,500
Market Cap 1,412,672,725
Sector Healthcare
Industry Medical - Devices
IPO Date 2021-07-30
Valuation
Profitability
Growth
Health
P/E Ratio -43.27
Forward P/E Ratio N/A
EPS -0.81
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 374
Country USA
Website RXST
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
*Chart delayed
Analyzing fundamentals for RXST we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see RXST Fundamentals page.

Watching at RXST technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RXST Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙